Semaglutide causes weight loss by mimicking a gut hormone called GLP-1, which acts on receptors throughout the brain to reduce hunger, increase fullness, and dampen the reward you get from eating. In clinical trials, people taking the 2.4 mg weekly dose lost roughly 15% of their body weight over about 16 months. But that headline number only makes sense once you understand the three overlapping mechanisms driving it.
It Tricks Your Brain Into Feeling Full
Your body naturally produces GLP-1 (glucagon-like peptide-1) after you eat. It’s a short-lived hormone that tells your brain the meal is over. Semaglutide is a synthetic version of GLP-1 that’s been engineered to last much longer in your body, about a week instead of minutes. That extended presence is what makes a once-weekly injection possible, and it’s what keeps the “I’m full” signal running almost continuously.
The signal travels through a network that starts in your gut. When your stomach stretches after a meal, GLP-1 triggers nerve pathways that relay information up through the brainstem to the hypothalamus, a small structure near the base of the brain that acts as your body’s appetite thermostat. Inside the hypothalamus, GLP-1 receptors sit on two types of neurons with opposing jobs: one type suppresses appetite, the other stimulates it. When semaglutide binds to those receptors, it turns up the appetite-suppressing neurons and turns down the hunger-promoting ones. The result is that you feel satisfied sooner during meals and stay satisfied longer afterward.
It Quiets Food Noise and Cravings
Hunger is only part of why people eat. The other part is reward, the pleasurable pull toward certain foods even when you’re not physically hungry. Scientists have found GLP-1 receptors scattered across brain regions involved in reward processing, including areas linked to craving, impulse control, and the emotional experience of eating. As one neuroscientist at the University of Cambridge describes it, reward is “the nice feeling you feel from eating chocolate that you don’t get from eating broccoli.”
Semaglutide appears to dial down that reward signal. Many people on the medication describe a phenomenon now commonly called “food noise,” the constant, intrusive background chatter about what to eat next, suddenly going quiet. One patient described walking past a bowl of popcorn, a snack she previously couldn’t resist, and feeling nothing. “All of a sudden it was like some part of my brain that was always there just went quiet,” she told Scientific American. This shift often happens early in treatment, sometimes within the first few weeks, and it represents something distinct from simply feeling less hungry. It’s a reduction in the mental preoccupation with food itself.
It Slows Your Stomach Down
Semaglutide also delays gastric emptying, the speed at which food leaves your stomach and enters your small intestine. When food sits in the stomach longer, stretch receptors keep sending fullness signals to your brain. You feel physically full for a longer period after eating a smaller portion.
This effect is strongest early in treatment, particularly during the first four weeks. By about 16 weeks of continued use, the delay in gastric emptying tends to diminish as the body partially adapts. That doesn’t mean the drug stops working. By that point, the brain-based appetite and reward effects are well established and continue driving weight loss independently of stomach motility.
It Regulates Blood Sugar Without Crashing It
Semaglutide was originally developed for type 2 diabetes, and its blood sugar effects contribute to weight loss in a subtle but important way. The drug enhances insulin release and suppresses glucagon (a hormone that raises blood sugar), but only when blood sugar is actually elevated. This glucose-dependent mechanism means it smooths out the spikes and crashes that can trigger reactive hunger. You’re less likely to feel that urgent, shaky need to eat two hours after a meal. The risk of hypoglycemia is very low precisely because the drug only acts when blood sugar is high.
How Much Weight People Actually Lose
The landmark STEP 1 trial tested semaglutide 2.4 mg in adults with obesity or overweight (with at least one weight-related condition) over 68 weeks. Participants also followed a reduced-calorie diet and increased physical activity. The average weight loss was about 15% of starting body weight, compared to roughly 2.4% in the placebo group. For someone starting at 230 pounds, that’s approximately 35 pounds.
Weight loss isn’t immediate. The FDA-approved dosing schedule starts at 0.25 mg per week for the first month, then gradually increases every four weeks, moving through 0.5 mg, 1 mg, and 1.7 mg before reaching the full 2.4 mg maintenance dose at week 17. This slow escalation exists primarily to reduce gastrointestinal side effects. Most of the meaningful weight loss happens after reaching the maintenance dose, with the curve continuing to trend downward through at least month 16.
Why Side Effects Happen
The same mechanisms that suppress appetite also cause the drug’s most common side effects. Delayed gastric emptying and altered gut signaling lead to nausea, vomiting, diarrhea, and constipation, especially during dose escalation. Compared to placebo, people taking semaglutide are roughly three times more likely to experience nausea, four times more likely to vomit, and nearly twice as likely to have diarrhea. Higher doses carry higher risk.
For most people, these effects are mild to moderate and improve over the first few months as the body adjusts. The gradual dose escalation helps, and if a particular dose increase triggers significant symptoms, guidelines allow delaying the next step by four weeks. A smaller number of people find the gastrointestinal effects severe enough to stop treatment.
What Happens When You Stop
Semaglutide treats obesity the way blood pressure medication treats hypertension: it works while you take it. A 2025 systematic review in The BMJ found that people regain weight at a rate of roughly 0.8 kg (about 1.8 pounds) per month after stopping newer, more effective GLP-1 drugs like semaglutide. The projected timeline for returning to baseline weight was approximately 1.5 years after discontinuation.
This isn’t a failure of the drug. It reflects the biology of obesity. The appetite-regulating pathways that semaglutide modifies don’t permanently reset. Once the drug is cleared from the body, hunger returns, food noise returns, and the reward system ramps back up. The hypothalamus, brainstem, and reward circuits revert to their prior signaling patterns. For this reason, most prescribing guidelines frame semaglutide as a long-term or indefinite treatment rather than a short course.